HER2 overexpression in various tumor types, focussing on its relationship to the development of invasive breast cancer

被引:108
作者
Ménard, S [1 ]
Casalini, P [1 ]
Campiglio, M [1 ]
Pupa, S [1 ]
Agresti, R [1 ]
Tagliabue, E [1 ]
机构
[1] Ist Nazl Tumori, Dept Expt Oncol, Mol Targeting Unit, I-20133 Milan, Italy
关键词
breast cancer; gene regulation; HER2; Herceptin; immunohistochemical; trastuzumab;
D O I
10.1023/A:1011151505425
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
To date, poor standardization in HER2 status evaluation has precluded reliable comparison of overexpression rates in different tumors. However, standardized methodologies have been introduced recently for these analyses, and have identified frequencies of 51%, 44%, 26% and 25% in Wilm's tumor, bladder, pancreatic and breast carcinoma, respectively. Other tumors tested had frequencies below 20%. The frequency was greater than that predicted by gene amplification data in some tumor types, which may indicate overexpression due to gene deregulation, rather than gene amplification. Analysis of a large retrospective series of breast carcinomas demonstrated an association between HER2 positivity and a number of other prognostic markers. Together, these variables identify a subset of tumors with poor prognosis and early relapse post-surgery. HER2 expression is relatively stable, with 95% concordance between the HER2 status of primary and metastatic lesions. However, contralateral tumors are unrestricted with regard to HER2 status. Preliminary data indicate that the HER2 status of a hormone receptor-positive tumor may fluctuate according to the menstrual cycle. It is anticipated that the emerging wealth of standardized data for HER2 status will help to elucidate the role of HER2 in tumor progression.
引用
收藏
页码:15 / 19
页数:5
相关论文
共 34 条
[1]  
Alexiev Borislav A., 1997, General and Diagnostic Pathology, V142, P271
[2]   OVEREXPRESSION OF HER-2 NEU AND ITS RELATIONSHIP WITH OTHER PROGNOSTIC FACTORS CHANGE DURING THE PROGRESSION OF INSITU TO INVASIVE BREAST-CANCER [J].
ALLRED, DC ;
CLARK, GM ;
MOLINA, R ;
TANDON, AK ;
SCHNITT, SJ ;
GILCHRIST, KW ;
OSBORNE, CK ;
TORMEY, DC ;
MCGUIRE, WL .
HUMAN PATHOLOGY, 1992, 23 (09) :974-979
[3]   OVEREXPRESSION OF THE C-ERBB-2 ONCOPROTEIN - WHY DOES THIS OCCUR MORE FREQUENTLY IN DUCTAL CARCINOMA INSITU THAN IN INVASIVE MAMMARY-CARCINOMA AND IS THIS OF PROGNOSTIC-SIGNIFICANCE [J].
BARNES, DM ;
BARTKOVA, J ;
CAMPLEJOHN, RS ;
GULLICK, WJ ;
SMITH, PJ ;
MILLIS, RR .
EUROPEAN JOURNAL OF CANCER, 1992, 28A (2-3) :644-648
[4]   Phase II study of weekly intravenous recombinant humanized Anti-p185(HER2) monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast [J].
Baselga, J ;
Tripathy, D ;
Mendelsohn, J ;
Baughman, S ;
Benz, CC ;
Dantis, L ;
Sklarin, NT ;
Seidman, AD ;
Hudis, CA ;
Moore, J ;
Rosen, PP ;
Twaddell, T ;
Henderson, IC ;
Norton, L .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (03) :737-744
[5]  
BECHHARDT RN, 1995, ARCH OTOLARYNGOL, V121, P1265
[6]  
COLOMER R, 1997, P AN M AM SOC CLIN, V16, pA140
[7]  
DATI C, 1990, ONCOGENE, V5, P1001
[8]  
Hilsenbeck S. G., 1993, Proceedings of the American Association for Cancer Research Annual Meeting, V34, P193
[9]   THE BIOLOGY OF ERBB-2 NEU HER-2 AND ITS ROLE IN CANCER [J].
HYNES, NE ;
STERN, DF .
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 1994, 1198 (2-3) :165-184
[10]   OVEREXPRESSION OF THE C-ERB-2 PROTEIN IN HUMAN-BREAST TUMOR-CELL LINES [J].
HYNES, NE ;
GERBER, HA ;
SAURER, S ;
GRONER, B .
JOURNAL OF CELLULAR BIOCHEMISTRY, 1989, 39 (02) :167-173